Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health
02 avr. 2019 10h02 HE
|
Admera Health, LLC
NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at...
Synergy CHC Corp. Announces Fiscal 2018 Year End Results
29 mars 2019 17h30 HE
|
Synergy CHC Corp
Westbrook, Maine, March 29, 2019 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (OTCQB: SNYR) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the fiscal...
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting
26 mars 2019 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...
Entrepix Receives Multiple Orders for New DSS-200 Synergy Cleaning Systems
09 juil. 2018 08h00 HE
|
Entrepix, Inc.
PHOENIX, July 09, 2018 (GLOBE NEWSWIRE) -- Entrepix Inc., a leading provider of wafer cleaning and chemical mechanical planarization (CMP) equipment and process services, today announced it has...
Metaswitch Recognized as Global Market Leader in Virtualized SBC
09 mai 2016 09h00 HE
|
Metaswitch Networks
LONDON, UNITED KINGDOM--(Marketwired - May 09, 2016) -
Network software provider Metaswitch Networks® is the market leader in global shipments of virtualized session border controllers...
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
18 nov. 2014 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for
RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple
Myeloma.
...
ShoreTel Surpasses 10,000 Enterprise Customers
27 juil. 2009 08h00 HE
|
ShoreTel
SUNNYVALE, CA--(Marketwire - July 27, 2009) - ShoreTel® (NASDAQ: SHOR), the leading
provider of brilliantly simple IP phone systems with fully integrated
Unified Communications (UC), today...